Thiogenesis Therapeutics Corp. has seen a notable decline in its stock performance this week, reflecting broader challenges in the healthcare sector.
Thiogenesis Therapeutics Corp. (TTI.V) has closed at C$0.51, marking a 7.41% decrease over the past week. The stock has struggled to maintain momentum, with no significant company news to drive investor interest. Let's delve into the technical indicators and performance metrics to understand the current landscape for Thiogenesis.
Advertisement
Thiogenesis Therapeutics Corp.
TTI.V
TTI.V
Thiogenesis Therapeutics Corp.
WealthAwesomeMarket cap
$34.99M
52W high
$0.81
52W low
$0.44
1W change
-7.41%
Beta
0.56
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TTI's historical volatility
30-Day Vol
61.6%
Annualized
90-Day Vol
58.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.43
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.48 | C$0.39 – C$0.59 |
| 60 trading days | C$0.45 | C$0.34 – C$0.61 |
| 90 trading days | C$0.43 | C$0.30 – C$0.62 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: With a low trading volume compared to its average and a downward trend in price, investors may need to approach Thiogenesis Therapeutics with caution while monitoring for any future developments.
Thiogenesis Therapeutics Corp. Stock Down 7.41% This Week
The stock's 1-month performance shows a decline of 9.09%, indicating ongoing challenges in the market.
Bull case
If the company can improve its operations and generate positive news or partnerships, there could be potential for a recovery in its stock price.
Bear case
Continued declines in stock price, along with negative earnings metrics, suggest that investor sentiment may remain weak in the near term.
Recent Price Action
Advertisement
Thiogenesis Therapeutics Corp. has experienced a challenging week, with its stock price settling at C$0.51. This represents a 7.41% decline over the past week and a significant 9.09% drop over the last month. Year-to-date, the stock has decreased by 23.08%, highlighting ongoing difficulties for the company in the healthcare sector.
Technical Picture
Analyzing the technical indicators, Thiogenesis is currently trading below its 50-day moving average of C$0.54 and its 200-day moving average of C$0.56, indicating a bearish trend. The stock has a 52-week range of C$0.44 to C$0.81, with its current price at approximately 19% of that range. The beta of 0.56 suggests that the stock is less volatile than the broader market, which may provide some stability amid fluctuations.
Volume Analysis
The latest trading volume for Thiogenesis was 2,500 shares, significantly lower than the 20-day average volume of 39,436 shares. This indicates a lack of investor interest and could contribute to the stock's downward pressure. A volume of 0.06x compared to the average suggests that the current trading activity is minimal, which may hinder price recovery efforts.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
